Georgia's Online Cancer Information Center


back

Sarcoma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Sarcoma
Cancer Type = Sarcoma
NCI ID Cancer Type Trial Name
There are currently 30 active Sarcoma clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Beta-only IL-2 ImmunoTherapY Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
2.
A Randomized Study Investigating Preoperative Chemotherapy Followed by Surgery versus Surgery Alone in Patients with High Risk Retroperitoneal Sarcoma, STRASS2 Trial
Cancer Type
Sarcoma
NCT ID
NCT04031677
Protocol IDs
EA7211
EA7211
NCI-2022-10255
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
3.
NCORP Trial
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT04994132
Protocol IDs
ARST2031
ARST2031
NCI-2021-06711
4.
A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases
Cancer Type
Sarcoma
NCT ID
NCT04554914
Protocol IDs
ATA129-EBV-205
NCI-2020-07698
2020-000177-25
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
5.
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Neuroblastoma, Sarcoma
NCT ID
NCT02644460
Protocol IDs
AFLACST1501
NCI-2015-02256
IRB00083793
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
6.
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, including CNS Tumors and Lymphoma
Cancer Type
Lymphoma, Sarcoma
NCT ID
NCT04870944
Protocol IDs
PEPN2111
PEPN2111
NCI-2021-03150
7.
NCORP Trial
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCT ID
NCT05366881
Protocol IDs
Adela-EDMRD-001
NCI-2022-04272
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
8.
Chemotherapy for the Treatment of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT05304585
Protocol IDs
ARST2032
ARST2032
NCI-2022-01012
9.
Childhood Cancer Survivor Study
Cancer Type
Brain & Spinal Cord Tumor, Hodgkin Lymphoma, Leukemia, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor
NCT ID
NCT01120353
Protocol IDs
CCSS
U24CA055727
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
10.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT05334069
Protocol IDs
A212102
A212102
A212102
NCI-2022-02477
Treatment Sites (1)
Low Country Cancer Care Associates, PC
Savannah
11.
Ensartinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor, Wilms Tumor
NCT ID
NCT03213652
Protocol IDs
APEC1621F
APEC1621F
APEC1621F
NCI-2017-01243
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
12.
Immunotherapy (Nivolumab and Ipilimumab) for the Treatment of Relapsed or Refractory INI-1 Negative Cancer
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Sarcoma
NCT ID
NCT04416568
Protocol IDs
20-041
NCI-2020-04573
13.
Informational Meetings for Planning and Coordinating Treatment, The IMPACT Trial
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Sarcoma, Solid Tumor
NCT ID
NCT04330833
Protocol IDs
IUSCC-0705
NCI-2021-01462
14.
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Cancer Type
Sarcoma
NCT ID
NCT06127407
Protocol IDs
CL3-95031-007
NCI-2024-03271
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
15.
Liquid Biopsy as a Prognostic and Response Diagnostic in Patients with Ewing Sarcoma and Osteosarcoma, LEOPARD Study
Cancer Type
Sarcoma
NCT ID
NCT06068075
Protocol IDs
18-138
NCI-2023-07461
16.
Losartan and Sunitinib for the Treatment of Relapsed or Refractory Osteosarcoma
Cancer Type
Sarcoma
NCT ID
NCT03900793
Protocol IDs
18-2740
NCI-2019-06119
18-2740.cc
17.
Modified Immune Cells (Autologous iC9.GD2.CAR.IL-15 T cells) for Treating Patients with Relapsed or Refractory High Risk Neuroblastoma, Ganglioneuroblastoma, or Osteosarcoma
Cancer Type
Neuroblastoma, Neurologocal Tumor, Sarcoma
NCT ID
NCT03721068
Protocol IDs
LCCC1743-ATL
NCI-2019-02083
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
18.
Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Teenagers or Young Adults with Recurrent or Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, or Soft Tissue Sarcoma
Cancer Type
Sarcoma
NCT ID
NCT02945800
Protocol IDs
MCC-18613
NCI-2016-01837
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
19.
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Cancer Type
Head and Neck Cancer, Sarcoma, Solid Tumor
NCT ID
NCT04541108
Protocol IDs
PBI-MST-01
NCI-2021-10892
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
20.
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Cancer Type
Colon/Rectal Cancer, Sarcoma, Solid Tumor
NCT ID
NCT03715933
Protocol IDs
Ph1 INBRX-109
NCI-2018-03556
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
21.
REtroperitoneal SArcoma Registry: an International Prospective Initiative
Cancer Type
Sarcoma
NCT ID
NCT03838718
Protocol IDs
201/16
NCI-2019-08030
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
22.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
23.
Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study
Cancer Type
Sarcoma, Solid Tumor
NCT ID
NCT04469530
Protocol IDs
AFLACST1903
STUDY00000113
NCI-2020-01654
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Winship Cancer Institute of Emory University
Atlanta
24.
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Cancer Type
Cervical Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Sarcoma, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary
NCT ID
NCT05103345
Protocol IDs
SGN-P01-002
NCI-2023-06281
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
25.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCT ID
NCT03155620
Protocol IDs
APEC1621SC
APEC1621SC
NCI-2017-01251
APEC1621SC
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
26.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Cancer Type
Brain Tumor, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Sarcoma, Uterine Cancer, Wilms Tumor
NCT ID
NCT04851119
Protocol IDs
PEPN2011
PEPN2011
NCI-2021-02852
27.
NCORP Trial
Testing Olaparib and Temozolomide versus the Usual Treatment for Uterine Leiomyosarcoma after Chemotherapy Has Stopped Working
Cancer Type
Sarcoma, Unknown Primary, Uterine Cancer
NCT ID
NCT05432791
Protocol IDs
A092104
A092104
NCI-2022-05065
NCT05432791
28.
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Cancer Type
Sarcoma
NCT ID
NCT05235165
Protocol IDs
AOST2031
AOST2031
NCI-2021-14237
29.
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Kidney Cancer, Sarcoma, Solid Tumor
NCT ID
NCT05286801
Protocol IDs
PEPN2121
PEPN2121
NCI-2022-01992
30.
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
Cancer Type
Sarcoma
NCT ID
NCT04616560
Protocol IDs
PEPN1924
NCI-2020-08428
PEPN1924
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Georgia CORE bridges the gap between groundbreaking research, educational outreach, and effective advocacy to transform the landscape of cancer care for all Georgians.